The Medicare prescription drug pricing plan Democrats unveiled is not nearly as ambitious as many lawmakers sought, but they and drug policy experts say the provisions crack open the door to reforms that could have dramatic effects. More changes are coming as consumers are tired of high drug prices while pharma reports record profits.

SUMMARY: Wegovy is selling so well that it’s hard to get at pharmacies. It’s being positioned as an anti-obesity drug, but one study by Novo Nordisk has shown that people who stop taking Wegovy after a few months tend to regain much of their lost weight within a year. In addition, people who lost weight on Wegovy in clinical trials had nutritional counseling and had to stay on a strict diet.

SUMMARY: Now that President Biden’s attempt to lower Medicare drug prices is dead, pharma can get back to business, and their business, of course, is making money. Using social media analytical tools, I was able to determine that there are a lot of outraged voters out there. Politics is broken and is too often about money, not what’s best for people.

SUMMARY: Large-cap pharma companies are trading higher in the morning hours after White House unveiled a framework for a deal on President Biden’s social spending package on Thursday leaving out a key provision that allowed Medicare to negotiate lower prescription drug prices. In 2019, Medicare Part D covered more than 3,500 prescription drug products, with total spending of $183 billion, not accounting for rebates. The plan to allow the government to negotiate drug prices for Medicare is dead due to big pharma buying politicians.